15

20

30

35


We claim:

- 1. A process for producing crystals of a GLP-1 analogue comprising:
- a) preparing an aqueous solution comprising a GLP-1 analogue, a salt, and an organic solvent, and
- b) isolation of the crystals after formation.
- 10 2. The process according to claim 1 wherein in step a) adjusting pH to pl-4<pH<pl, or to pl<pH<pl+4, wherein pl is the isoelectric point of the GLP-1 analogue.</p>
  - The process according to any one of claims 1-2 wherein the crystals are needle shaped crystals of a GLP-1 analogue.
  - 4. The process according to any one of claims 1-3 wherein the crystals has a length of at least  $0.5\mu\text{m}.$
  - The process according to any one of claims 1-4 wherein the GLP-1 analogue in the aqueous solution has a purity of less than 95%, as measured by HPLC.
  - 6. The process according to any one of claims 1-5 wherein the GLP-1 analogue in the aqueous solution is present in a concentration of at least 0.5 mg/ml.
- 7. The process according to any one of claims 1-6 wherein the GLP-1 analogue is selected from non-synthetic GLP-1 analogues.
  - 8. The process according to any one of claims 1-7 wherein the GLP-1 analogue is  ${\rm Arg}^{34}{\rm GLP}$ -1(7-37) or  ${\rm Arg}^{26}{\rm GLP}$ -1(7-37).
  - 9. The process according to any one of claims 1-8 wherein the salt is present in a concentration of at least 25 mM.
  - 10. The process according to any one of claims 1-9 wherein the organic solvent is present in a concentration of from 0.5 to 50 %(vol/vol).

10

15

20



- 5 12. A method for producing a GLP-1 analogue or a GLP-1 analogue whereto is attached a lipophilic substituent comprising the steps:
  - a) preparing an aqueous solution comprising a GLP-1 analogue, a salt, and an organic solvent, and
  - b) isolation of the crystals after formation.
  - 18. Crystals of a GLP-1 analogue optainable by the process comprising:
    - a) preparing an aqueous solution comprising a GLP-1 analogue, a salt, and an organic solvent, and
  - b) isolation of the crystals after formation.
  - 14. Needle shaped crystals of a GLP-1 analogue.
  - 16. A pharmaceutical composition comprising needle shaped crystals of a GLP-1 analogue and a pharmaceutically acceptable carrier.

25-01-01 LBKi/VMN